Therapeutic Areas | Overview

The BioTherapeutics Commitment

BioTherapeutics is committed to developing therapies with the aim of saving and sustaining lives. Our aim is to provide the highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.

The BioTherapeutics' team specializes in three key therapeutic areas: immunoglobulins, pulmonology, and critical care therapies.

back to top

Immunoglobulin Therapy

BioTherapeutics' immunoglobulin therapies treat primary immunodeficiencies (PIs) associated with defects in humoral immunity or a lack of antibody production. In addition to immunoglobulin therapies, BioTherapeutics also produces antibody-replacement therapies to bolster the immune system of people with secondary immunodeficiencies and recurrent infections. Immunoglobulin therapies also include treatments for immune thrombocytopenic purpura ITP in patients with low platelet counts.
For additional resources, please click here.

back to top

Pulmonology Therapy

Pulmonology therapy focuses on patients with alpha-1 antitrypsin deficiency (AATD). These patients have reduced levels of alpha-1 antitrypsin (AAT) protein in their blood.
For additional resources, please click here.

back to top

Critical Care Therapy

BioTherapeutics' critical care therapies includes albumin which is primarly used as plasma-volume replacement therapy for the treatment of hypovolemia. Baxter is the only company to offer albumin in a flexible, plastic container. Other critical care therapies include Protein C for patients with severe congenital Protein C deficiency.
For additional resources, please click here.

All of our therapies are developed to meet highest industry standards. As a leader in these markets, BioTherapeutics is focused on leading edge science and technology to advance treatment standards for our patients and their families.

back to top